Year-End Offer: 20% Off Online Orders
EOY2026
Ends Deccember 31, 2026

CAR DETECTION & CHARACTERIZATION

Connect CAR expression with target recognition by flow cytometry

Build a more complete picture of cells expressing a chimeric antigen receptor (CAR). Conigen’s novel cell surface antigen-based fusion proteins help you measure target-specific binding alongside CAR surface expression by flow cytometry.

For CAR construct design and screening, cell characterization, and assay development.

See the evidence.

CONSTRUCT COMPARISON: CD19

Similar CAR expression.
Different target binding.

B1 construct B2 construct

% anti-linker CAR expression cells

B1 97%
B2 100%

% CD19 specific CAR-binding cells

B1 45%
B2 95%

Conigen construct-comparison data. Explore all three measurements.

THREE MEASUREMENTS. THREE QUESTIONS.

CAR expression alone
does not tell the whole story.

Two constructs can look equivalent by anti-linker CAR staining. Adding target-specific binding is critical to reveal how they differ and their potential function.

01 / EXPRESSION

Is the CAR present on the cell?

Anti-linker or anti-tag staining identifies cells expressing the CAR construct.

CAR-positive cells

02 / TARGET RECOGNITION

Can the CAR bind its intended target?

A recombinant target antigen assesses the CAR’s binding to its intended target.

Target-binding cells

03 / FUNCTIONAL ACTIVITY

Does target recognition translate into functional activity?

A CAR T cell mediated tumor cell killing assay reveals the correlation between functional activity and target recognition.

Tumor-cell depletion

Antigen-Specific CAR Detection

Diagram showing a CD20-ECL2 scaffold protein binding a CD20-targeting CAR’s scFv, with APC-labeled anti-His antibody providing a fluorescent signal to detect surface CAR expression. Alternative anti-linker and anti-tag detection sites, the transmembrane region, and intracellular signaling domains are also shown.

CD20-ECL2 scaffold binding to the CAR is detected by anti-His APC, alongside anti-linker and anti-tag detection.

THE ANTIGEN–CAR INTERACTION

Make target recognition part of the picture.

In this example, the CD20 extracellular loop 2 (ECL2) scaffold binds the CAR. A fluorescent anti-His antibody detects the His-tag on the bound scaffold protein, while anti-linker or anti-tag staining measures CAR expression by flow cytometry.

Diagram of a chimeric antigen receptor (CAR), showing antibody variable heavy (VH) and light (VL) domains for antigen recognition, a tag and hinge region, a transmembrane (TM) anchor, and intracellular domains that transmit signals into the cell after antigen binding.

Key components of an scFv-based CAR.

FDA GUIDANCE / JANUARY 2024

Direct detection and antigen recognition matter.

“Flow cytometry allows assessment of multiple CAR T cell attributes throughout the manufacturing process (e.g., cell viability, identity, purity, strength).”

“We recommend direct detection of the CAR to determine the percentage of CAR-positive cells. If the CAR is detected by surrogate protein expression (e.g., detection of a co-expressed gene) or other broad-specificity reagents (e.g., protein L), you should evaluate the correlation with CAR expression.”

“Nonclinical evaluation of the antigen recognition domain should include assessment of the specificity and affinity/avidity for the target antigen/cells to evaluate the potential for on-target/off -tumor and off-target toxicities.”

FDA, Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products. January 2024. This recommendation does not specify a particular detection reagent.

LET’S TALK ABOUT YOUR CAR

Your target.
Your construct.
A comprehensive measurement.

Developing a CAR construct or choosing a detection reagent? Tell us about your target, sample type, and staining workflow. We can help you explore available formats and supporting data.

THE EVIDENCE

See what expression
alone can miss.

Conigen used complementary measurements of CAR expression by anti-linker staining and antigen binding to compare CD19 CAR constructs. A tumor-cell killing assay provided an independent functional activity evaluation.

CD19 CAR construct comparison
Design change Construct % anti-linker
CAR expression cells
% CD19 specific
CAR-binding cells
Tumor-cell
killing¹
VH/VL orientation A1 100%91%67%
A2 100%91%42%
Leader sequence B1 97%45%43%
B2 100%95%56%
Intracellular domains C1 87%60%48%
C2 100%97%63%

¹ Effector-to-target ratio of 0.5:1. 

B1 vs. B2

CAR expression looks similar. Antigen-binding reveals a difference.

CAR-positive staining is 97% versus 100%, while CD19 binding is 45% versus 95%. B2 also shows greater tumor-cell depletion: 56% versus 43%.

A1 & B1

Target recognition adds meaningful information.

A1 and B1 CAR constructs show similar high expression.  A1 has greater CAR binding (91%) and tumor-cell killing (67%) while B1 has lower CAR binding (45%) and tumor-cell killing (43%).  

A1 and A2 also have equal expression and binding but different depletion results—showing why functional testing remains a separate layer.

BUILT AROUND THE TARGET

Protein design shapes
what you can measure.

Target antigens need to preserve relevant binding sites. Conigen selects protein architectures for the structure of each target and evaluates binding to known antibodies or ligands.

Diagram of a soluble protein dimer(CD19) with two extracellular domain (ECD) chains joined by a dimerization motif, illustrating how two copies of an antigen can be presented together for antibody or CAR binding.

CD19

An extracellular domain presented as a dimer.

A multivalent, Fc-free design presents the CD19 extracellular domain for target-specific CAR binding measurements.

Flow cytometry histogram showing higher anti-His APC fluorescence for the CD19-labeled population (purple) than the mock control (gray), indicating increased binding of the His-tagged detection reagent.

CD19-specific CAR detection (anti-His-APC)

Diagram of a membrane protein with its 54-amino-acid extracellular domain (ECD) highlighted above the lipid bilayer, showing the portion exposed outside the cell and accessible for antibody binding.

BCMA

A short extracellular domain

A different Fc-free scaffold supports presentation of BCMA’s shorter extracellular domain.

Flow cytometry histogram showing higher anti-His APC fluorescence with BCMA staining (purple) than the mock control (gray), consistent with binding of the His-tagged BCMA reagent and detection of BCMA-targeting CARs on the cell surface.

BCMA-specific CAR detection (anti-His-APC)

Diagram of CD20 extracellular loop 2 (ECL2), shown in blue on a gray protein scaffold, illustrating how the scaffold presents the loop for recognition by CD20-targeting antibodies or CARs.

CD20

An extracellular loop

A scaffold presents CD20’s second extracellular loop, a region recognized by rituximab-based CARs.

Flow cytometry histogram showing higher anti-His APC fluorescence with CD20-ECL2 staining (purple) than the mock control (gray), consistent with binding of the His-tagged CD20-ECL2 reagent and detection of CD20-targeting CARs on the cell surface.

CD20-specific CAR detection (anti-His-APC)

Choose a format for your staining workflow.

Depending on the target, available formats include His-tag, AviTag, and biotinylated protein reagents.  Detection signal may use a fluorescently conjugated anti-His-tag or anti-AviTag, or a biotin-compatible signal readout by flow cytometry.  Fc-free formats remove the FcR binding concern; protein format and assay suitability should be evaluated to fit your construct and sample.

EXPLORE YOUR RESEARCH AREA

Find the target.
Build the right assay.

Explore Conigen’s cell surface antigen-based  fusion proteins in different disease and research areas. Linked targets open available product examples. These groups are a starting point: target expression and relevance can span several settings.

01

Purple and orange cells with Y-shaped antibody-1

B-cell/plasma-cell malignancies targets

02

Purple and orange cells with pale nuclei-2

Myeloid malignancies targets

06

Illustration of a green cell interacting with an orange cell through a purple surface receptor, with a purple Y-shaped antibody above, representing molecular recognition and antibody targeting in cell interactions.

Autoimmune CAR-T targets

07

Illustration of an orange magnifying glass highlighting a purple cell-like shape beside two green shapes, representing the detection and identification of a target cell within a mixed population.

CAR-T manufacturing and characterization

Questions?

Available formats and supporting data differ by target. Discuss your construct and detection needs with our team.

LET’S TALK ABOUT YOUR CAR

Your target.
Your construct.
A comprehensive measurement.

Developing a CAR construct or choosing a detection reagent? Tell us about your target, sample type, and staining workflow. We can help you explore available formats and supporting data.

2026 Year-End Offer Terms

2026 Year-End Promotion

Save 20% on all Conigen catalog products when you order online at www.conigen.com using promo code EOY2026.

  • Offer valid: Through December 31, 2026.

  • Promo code: EOY2026

  • Discount: 20% off all catalog products.

  • Online orders only: Discount must be applied at checkout on conigen.com. Orders placed by email, phone, or quotation are not eligible.

  • Exclusions: Custom products and custom services are excluded.

  • Other offers: This promotion cannot be combined with other discounts, promotions, or special offers.

Offer valid for eligible online purchases only.